What Happened

Pfizer's phase 2/3 trial of Paxlovid in children aged 6-17 showed robust SARS-CoV-2 RNA reduction and no COVID-related hospitalizations or deaths. The study, published in Pediatrics, provides pharmacokinetic data supporting potential EUA expansion for younger children.

Who Is Affected

Pediatric infectious disease specialists and hospital antimicrobial stewardship programs treating high-risk children (6-12 years) with conditions like chronic lung disease or diabetes. Boston Children's Hospital clinicians are already evaluating the data for clinical implications.

Market Impact

• Creates potential $ opportunity as Paxlovid could displace remdesivir (current only option for <12yo)
• Pediatric Infectious Diseases Society already recommends Paxlovid for eligible patients
• Infectious Diseases Society of America updating COVID guidelines to include pediatrics

What to Watch

Pfizer's next regulatory move - whether they'll seek full FDA approval for 6+ year olds. Also monitor IDSA's upcoming pediatric COVID treatment guidelines, likely to reference this data.